Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $5.67

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.67.

Separately, HC Wainwright dropped their target price on Karyopharm Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 1st.

Insider Transactions at Karyopharm Therapeutics

In other news, CFO Michael Mason sold 27,687 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $32,393.79. Following the completion of the sale, the chief financial officer now owns 404,918 shares in the company, valued at $473,754.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Richard A. Paulson sold 80,470 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the completion of the sale, the chief executive officer now owns 1,183,783 shares in the company, valued at $1,385,026.11. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Michael Mason sold 27,687 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $32,393.79. Following the completion of the sale, the chief financial officer now owns 404,918 shares of the company's stock, valued at approximately $473,754.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 164,542 shares of company stock worth $198,175. Company insiders own 3.32% of the company's stock.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. Bleakley Financial Group LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at approximately $29,000. Advisor Group Holdings Inc. lifted its position in shares of Karyopharm Therapeutics by 134.3% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,906 shares of the company's stock valued at $30,000 after acquiring an additional 5,105 shares during the period. Simplicity Solutions LLC acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at approximately $33,000. Prelude Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at approximately $53,000. Finally, State of Wyoming lifted its position in shares of Karyopharm Therapeutics by 188.8% during the 4th quarter. State of Wyoming now owns 17,082 shares of the company's stock valued at $58,000 after acquiring an additional 11,168 shares during the period. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI traded down $0.11 during mid-day trading on Friday, hitting $1.17. The stock had a trading volume of 1,441,884 shares, compared to its average volume of 1,071,796. The firm's 50 day moving average is $1.34 and its 200 day moving average is $1.05. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $4.11. The stock has a market capitalization of $134.63 million, a price-to-earnings ratio of -0.94 and a beta of 0.03.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $33.75 million during the quarter, compared to analysts' expectations of $33.50 million. During the same period in the prior year, the company posted ($0.43) earnings per share. As a group, equities research analysts expect that Karyopharm Therapeutics will post -1.19 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).